Factors influencing mortality in COVID-19-associated mucormycosis: The international ID-IRI study

Basit Öğe Kaydı
dc.authoridSahin, Meyha/0000-0003-4147-3587
dc.authoridErdem, Hakan/0000-0002-6265-5227
dc.authoridHakamifard, Atousa/0000-0001-9456-2239
dc.authoridBabamahmoodi, Abdolreza/0000-0002-3730-5268
dc.authoridRashid, Naveed/0009-0002-9549-1289
dc.contributor.authorSahin, Meyha
dc.contributor.authorYilmaz, Mesut
dc.contributor.authorMert, Ali
dc.contributor.authorNaghili, Behrouz
dc.contributor.authorRavanbakhsh, Fatemeh
dc.contributor.authorVarshochi, Mojtaba
dc.contributor.authorDarazam, Ilad Alavi
dc.date.accessioned2025-01-27T20:29:09Z
dc.date.available2025-01-27T20:29:09Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractThe emergence of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), triggered a global pandemic. Concurrently, reports of mucormycosis cases surged, particularly during the second wave in India. This study aims to investigate mortality factors in COVID-19-associated mucormycosis (CAM) cases, exploring clinical, demographic, and therapeutic variables across mostly Asian and partly African countries. A retrospective, cross-sectional analysis of CAM patients from 22 medical centers across eight countries was conducted, focusing on the first 3 months post-COVID-19 diagnosis. Data collected through the ID-IRI included demographics, comorbidities, treatments, and outcomes. A total of 162 CAM patients were included. The mean age was 54.29 +/- 13.04 years, with 54% male. Diabetes mellitus (85%) was prevalent, and 91% had rhino-orbital-cerebral mucormycosis. Surgical debridement was performed in 84% of the cases. Mortality was 39%, with advanced age (hazard ratio [HR] = 1.06, [P < .001]), rituximab use (HR = 21.2, P = .05), and diabetic ketoacidosis (HR = 3.58, P = .009) identified as risk factors. The mortality risk increases by approximately 5.6% for each additional year of age. Surgical debridement based on organ involvement correlated with higher survival (HR = 8.81, P < .001). The utilization of rituximab and diabetic ketoacidosis, along with advancing age, has been associated with an increased risk of mortality in CAM patients. A combination of antifungal treatment and surgical intervention has demonstrated a substantial improvement in survival outcomes.
dc.identifier.doi10.1093/mmy/myae064
dc.identifier.issn1369-3786
dc.identifier.issn1460-2709
dc.identifier.issue7
dc.identifier.pmid38914466
dc.identifier.scopus2-s2.0-85199223686
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1093/mmy/myae064
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22842
dc.identifier.volume62
dc.identifier.wosWOS:001272180500001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherOxford Univ Press
dc.relation.ispartofMedical Mycology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectCOVID-19
dc.subjectCOVID-19-associated mucormycosis
dc.subjectimmunosuppression
dc.subjectmortality
dc.titleFactors influencing mortality in COVID-19-associated mucormycosis: The international ID-IRI study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu